Protein Biochips Market Analysis

By Technology (Microarrays, Microfluidics)

The microarrays segment is estimated to hold 60% share of the global protein biochips market in the year 2036. The growth of the segment can be attributed to the increasing preference for microarrays owing to its ability to detect multiple biomarkers in a single assay, as well as its ability to generate higher throughput data compared to other technology-based protein biochips. Additionally, the rising demand for protein biochips for personalized medicine and drug discovery is also expected to contribute to the growth of the microarray segment. According to a study, there are 73,000 genetic testing products, and 250-300 personalized medicines that are currently available for cancer patients, genetic rare disease patients, and people with chronic and infectious diseases.

End-User (Biotechnology & Pharmaceutical Companies, Hospitals & Diagnostics Centres, Academic & Research Institutes)

By end-user segment, the biotechnology & pharmaceutical companies’ market is expected to gain growth of 35% by the year 2036. The growth of this segment can be attributed to the increasing number of biotechnology companies, growth in the biopharmaceutical Industry and, increasing numbers of clinical trials for the development of innovative medicines and treatments. According to the US National Library of Medicine, there are 446,246 clinical trials taking place in all 50 states and in 221 countries as of March 2023. Furthermore, the advancement in technology capabilities is also enabling the development of more targeted and precision medicine and treatments, further stimulating the growth of the segment.

Our in-depth analysis of the global market includes the following segments: